comparemela.com

Novartis Us News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innovation And Healthcare Meet At Novartis

Novartis US executive Andrea Marazzi shares his view on innovation, healthcare challenges, and leadership amid the evolving landscape of medicine.

United statesStephanie ricciAndrea marazziNorth americaCountry presidentNovartis canadaCommercial strategyInnovation in healthcareNovartis us

Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal.

United statesMarrow transplant researchInternational bloodInternational prognostic scoring systemsPresentation detailsNovartis us

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic.

United statesIsabella zinckVivek subbiahPrnewswire novartisSamir shahParag mahantiSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationExchange commissionApproval programRare oncology agnostic researchNovartis pharmaceuticals corp

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic.

United statesIsabella zinckVivek subbiahPrnewswire novartisSamir shahParag mahantiSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationExchange commissionApproval programRare oncology agnostic researchNovartis pharmaceuticals corp

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif® (bosutinib) at 96.

United statesEast hanoverJeff legosJorgee cortesSloan simpsonPrnewswire novartisAmerican society of clinical oncologyEuropean hematology associationExchange commissionGlobal head of oncology hematology developmentApproval programAugusta universityNj novartis pharmaceuticals corporationGeorgia cancer centerNovartis pharmaceuticals corpClinical oncology

vimarsana © 2020. All Rights Reserved.